Active Ingredient(s): Darunavir + Cobicistat + Emtricitabine + Tenofovir Alafenamide
FDA Approved: * July 17, 2018
Pharm Company: * JANSSEN PRODS
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Symtuza Overview

Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen. Brand name(s) Ingredients (INN) Food and Drug Administration (FDA) approval date European Medicines Agency (EMA) approval date Health Canada approval date Company Single-tablet regimen? NRTIs / NtRTIs NNRTI INSTI PI PK enhancer Combivir lamivudinezidovudine September 26, 1997 ViiV Healthcare No Kaletra (developed coun...

Read more Symtuza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Symtuza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Darunavir + Cobicistat + Emtricitabine + Tenofovir Alafenamide
  • Tablet: 150mg + 800mg + 200mg + 10mg, 800mg + 150mg + 200mg + 10mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Symtuza: (1 result)

Sorted by National Drug Code
  • 59676-800 Symtuza Oral Tablet, Film Coated by Janssen Products Lp

Drugs with one or more similar ingredients: (26 results)